WRLFMD Quarterly Report October-December 2014 FMD Ref Lab Report... · WRLFMD Quarterly Report ......
41
WRLFMD Quarterly Report April to June 2017 Foot-and-Mouth Disease
Transcript of WRLFMD Quarterly Report October-December 2014 FMD Ref Lab Report... · WRLFMD Quarterly Report ......
WRLFMD Quarterly Report
April to June 2017
Foot-and-Mouth Disease
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
2
CONTENTS
1. Summary of samples tested and reported FMD outbreaks ............................... 3
1.1. Asia ............................................................................................................... 3
1.2. Africa ............................................................................................................. 5
1.3. South America ............................................................................................... 6
1.4. Uncharacterised FMD viruses ....................................................................... 6
2. Detailed Analysis ............................................................................................... 8
2.1. ASIA .............................................................................................................. 9
2.2. AFRICA ....................................................................................................... 22
3. Vaccine matching ............................................................................................ 25
4. Annex 1 ........................................................................................................... 26
4.1. Summary of Submissions ........................................................................... 26
4.2. Clinical Samples .......................................................................................... 26
4.3. Antigenic Characterisation .......................................................................... 31
5. Annex 2 ........................................................................................................... 33
6. Annex 3 ........................................................................................................... 41
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
3
1. Summary of samples tested and reported
FMD outbreaks
1.1. Asia
Cambodia
Samples were received on 23rd May 2017 from the OIE Regional Reference Laboratory (RRL) in Pakchong (Thailand). Virus isolation and typing results are pending.
Iran
Twenty four samples from cattle and sheep were received on 8th May 2017. They were collected between October 2016 and February 2017 in various locations. FMDV type O was isolated from nine samples and type A also from nine samples. VP1 sequencing showed that all nine type O viruses belonged to the ME-SA/PanAsia-2 lineage with eight belonging to the ANT-10 sub-lineage and one belonging to the QOM-15 sub-lineage (see below). Two of the type A viruses belonged to the ASIA/G-VII lineage and the other seven belonged to the Iran-05 lineage (with six belonging to the FAR-09 sublineage and one belonging to the FAR-11 sublineage) (see below); findings that indicate that multiple serotype A lineages (with different antigenic properties) are currently co-circulating in the region.
Israel
Two outbreaks of FMD type A were reported in cattle in the Hazafon (Northern) district on 1st May 2017 and 22nd May 2017. VP1 sequencing, performed at the Kimron Veterinary Institute, showed that the causative virus belonged to the ASIA/G-VII lineage (see below). Another outbreak, due to FMD type O, in cattle at Haifa was shown to be due to the EA-3 topotype and closely related to viruses present in the West Bank of the Palestinian Autonomous Territories (see below).
Mongolia
Between 2nd February and 11th April 2017, 13 outbreaks of FMD type O were reported in cattle, sheep and goats in four provinces (Sukhbaatar, Dornod, Khentii and Dornogovi) in the east of the country. A batch of 16 samples were received on the
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
4
08/05/2017 which had been collected between March 2015 and May 2017. These were typed as FMDV type O (two collected in 2015 and eight collected between January and April 2017) and type A (collected from cattle and sheep in September 2016). The type O viruses from 2015 belonged to SEA/Mya-98 and ME-SA/PanAsia lineages, while those from 2017 all belonged to the PanAsia lineage (see below). The type A viruses from 2016 belonged to the ASIA/Sea-97 lineage (see below).
Myanmar
An outbreak of FMD type Asia 1 was reported in cattle in Rakhine State in January 2017. The last time this serotype was recorded in Myanmar was 2001. A sample received from the OIE RRL in Pakchong (Thailand) was typed as Asia 1 (although not virus could be isolated in cell cultures). VP1 sequencing of this sample, along with sequence received from the RRL, confirmed the presence of the Asia 1/G-VIII lineage showing the closest relationship to viruses from Bangladesh (see below). Additionally three samples, collected from cattle in January and April 2017 (Sagaing and Yangon regions), were typed as FMD type O and belonged to the ME-SA/Ind-2001d lineage (see below).
Laos
Two samples were received from the RRL on 23rd May 2017. They had been collected from cattle in January 2017 in Vientiane City and Champasak. Both were FMDV type O and belonged to the SEA/Mya-98 lineage (see below).
Palestinian Autonomous Territories
Four outbreaks of FMD type O were reported in cattle, sheep and goats in the West Bank between 1st May 2017 and 5th June 2017. VP1 sequencing, performed at the Kimron Veterinary Institute (Israel) showed the causal virus to belong to the EA-3 topotype (see below).
People’s Republic of China
Two outbreaks of FMD type O have been reported in Guangdong province on 23rd March 2017 (pigs) and 15th May 2017 (cattle). Another outbreak of FMD type O was reported in cattle in the Xinjiang Autonomous region on 16th April 2017. Two outbreaks of FMD type A were also reported in cattle in Xinjiang on the 24th April 2017 and 28th April 2017 (these had previously been notified on 9th May within an OIE follow-up about foot-and-mouth disease serotype O). No genotyping has so far been reported.
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
5
Thailand
Twenty eight samples, collected between August 2016 and February 2017 from various locations, were received from the RRL. FMDV type O was identified in 18 and type A in 10. VP1 sequencing revealed all the type O viruses to belong to the SEA/Mya-98 lineage and all the type A viruses to the ASIA/Sea-97 lineage (se below).
1.2. Africa
Algeria
Three further outbreaks of FMD type A were reported in cattle at Medea and Bordj Bou Arreridj on 2nd April 2017 and Setif on 7th April 2017. The latter outbreak was originally thought to be caused by SAT 1, but laboratory investigations confirmed that only type A was present. Genotyping at IZSLER and the WRLFMD showed the virus to belong to genotype IV of the AFRICA topotype (see below).
Ethiopia
Two batches of samples were received, one on 11th April 2017 and the other on 15th May 2017.
The first batch were samples collected from cattle between February 2016 and March 2017 from various locations in Oromia Region and Addis Ababa. FMD type O viruses were isolated from 17 samples and VP1 sequencing showed that those collected in 2016 (n=13) all belonged to the EA-4 topotype while the four collected in 2017 belonged to the EA-3 topotype.
The second batch consisted of 54 samples (some original epithelium and other cell culture isolates) collected from cattle between January 2016 and April 2017 in the Oromia Region and Addis Ababa. FMD type O viruses were recovered from only 14 samples (six epithelium and eight cell culture passaged), while FMDV genome was detected in a further 19 samples and 21 were NVD. VP1 sequencing revealed all 14 viruses isolated belonged to the EA-4 topotype (all were from 2016).
South Africa
A further outbreak of FMD type SAT 2 was reported in cattle on 24th March 2017 at Bushbuckridge, Mpumalanga. No genotyping has yet been reported. This outbreak is located in South Africa's FMD Protection Zone, which is not part of the FMD Free Zone and therefore does not affect South Africa's OIE recognised FMD free status.
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
6
Tunisia
Two outbreaks of FMD type A were reported in cattle in Bizerte on 24th April 2017. Local sequencing suggested a close relationship of the virus to the AFRICA/G-IV virus from Algeria. Analysis in one of the OIE Reference Laboratories is awaited.
Zambia
An outbreak of FMD (untyped) occurred in cattle in Mbala on 22nd March 2017. Further analyses are awaited.
Zimbabwe
Two outbreaks of FMD type SAT 2 were reported in cattle on 22nd March 2017 and 17th May 2017. They occurred in Matabeleland North and Midlands provinces, respectively, and are a continuation of outbreaks which have occurred since June 2015. No genotyping has been reported.
1.3. South America
Colombia
An outbreak of FMD type O was reported in cattle at La Marota, Curipao, Tame, Arauca on 11th June 2017. This is the first FMD outbreak in Colombia since August 2009, and anywhere in the continent of South America since outbreaks in Venezuela were recognised in 2013. Genotyping results are awaited.
1.4. Uncharacterised FMD viruses
A number of outbreaks have occurred where samples have not been sent to the WRLFMD. It is probable that the countries involved have performed their own genetic characterisation; however, through the OIE/FAO laboratory network we would also like to encourage the submission of samples (or complete VP1 sequences) to the WRLFMD.
An up-to-date list and reports of FMD viruses characterised by sequencing can be found at the following website: http://www.wrlfmd.org/fmd_genotyping/2017.htm.
Results from samples or sequences received at WRLFMD (status of samples being tested) are shown in Table 1 and a complete list of clinical sample diagnostics made by the WRLFMD from April to June 2017 is shown in Annex 1 (Summary of
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
7
Submissions). A record of all samples received by WRLFMD (April to June 2017) is shown in Annex 1 (Clinical Samples).
Table 1: Status of sequencing of samples or sequences received by the WRLFMD from April to June 2017 (* indicates samples carried over from the last quarter)
WRLFMD Batch No. Date
received Country Serotype
No. of
samples
No. of
sequences
Sequencing status
WRLFMD/2017/00006 18/04/2017 Algeria A 3 3 Completed
WRLFMD/2017/00007 11/04/2017 Ethiopia O 17 17 Completed
WRLFMD/2017/00008 13/04/2017 Iran O 9 9 Completed
WRLFMD/2017/00008 13/04/2017 Iran A 9 9 Completed
WRLFMD/2017/00009 15/05/2017 Ethiopia O 14 14 Completed
WRLFMD/2017/00010 08/05/2017 Mongolia O 8 8 Completed
WRLFMD/2017/00010 08/05/2017 Mongolia A 2 2 Completed
WRLFMD/2017/00011 23/05/2017 Thailand O 18 18 Completed
WRLFMD/2017/00011 23/05/2017 Thailand A 10 10 Completed
WRLFMD/2017/00012 23/05/2017 Myanmar O 3 3 Completed
WRLFMD/2017/00012 23/05/2017 Myanmar Asia 1* 1 1 Completed
WRLFMD/2017/00013 23/05/2017 Laos O 2 2 Completed
WRLFMD/2017/00015 23/05/2017 Cambodia Pending - - Pending
Total 96 96
*, no virus isolated on cell culture
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
8
2. Detailed Analysis
Key for maps and trees:
Serotype O
Serotype A
Serotype C
Serotype Asia-1
Serotype SAT 1
Serotype SAT 2
Serotype SAT 3
FMDV Genome Detected
No Virus Detected
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
9
2.1. ASIA
Iran
Batch: WRLFMD/2017/00008
Date received: 13/04/2017
No. of samples: 24
O (ME-SA/PanAsia-2/ANT-10): 8
O (ME-SA/PanAsia-2/QOM-15): 1
A (ASIA/G-VII): 2
A (ASIA/Iran-05/FAR-09): 6
A (ASIA/Iran-05/FAR-11): 1
FMDV-GD: 4
NVD: 2
Iran continued on next page
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
10
Iran continued
EURO-SA
AFRICA
ASIA
Iran-99 Iran-87 A15 A24 A12G-III
SIS-12 ESF-10 ARD-07 EZM-07
QAZ-11
FAR-11
HER-10AFG-07 Iran-05
AFG-07
FAR-09
BAR-08
SIS-10
FAR-09
A22Iran-96
G-VII
Cruzeiro/BRA/55*UKG/119/32
KEN/3/64
100
IRN/22/99IRN/2/87
Bangkok/TAI/60*
IRN/9/2011IRN/1/2005
TUR/33/200898
TUR/1/200887
IRN/9/2010IRN/15/2012PAK/14/2013
PAK/8/2013 PAK/25/2013 PAK/22/2014 PAK/21/2013
PAK/5/2013
100 AFG/5/2013 AFG/15/2013 PAK/6/2013
PAK/1/2013 PAK/48/2012
PAK/19/2013 PAK/13/2013 PAK/11/2013PAK/23/2014 PAK/17/2013
AFG/28/2013 AFG/32/2013
AFG/30/2013
98
99
BAL/PAK/iso-2/2011_A*86IRN/1/2011
IRN/7/2017
99
AFG/10/2010
IRN/15/2009 AFG/6/2010
AFG/6/2007IRN/197/2010IRN/201/2010
99IRN/188/2010
100
IRN/78/2009BAR/6/2008
AFG/42/2011 AFG/12/2011
100
IRN/125/2010PAK/32/2014
98 PAK/9/2015IRN/5/2015
100
PAK/42/2014
PAK/3/2015 PAK/7/2015
98 PAK/38/2014
IRN/27/2013 PAK/8/2014
86IRN/28/2013
PAK/14/2014 PAK/10/2014
96
IRN/34/2016 PAK/53/2015
IRN/9/2017
IRN/10/2017
74 IRN/6/2017 IRN/13/2017
IRN/2/201799
94
100
100
IRN/1/96IRQ/24/64
IND/40/2000*SAU/16/95
95
IRN/4/2017
IRN/12/2015IRN/25/2015ARM/2/2015
IRN/27/2015 IRN/20/2016
TUR /198/2015.808* ARM/1/2015
86IRN/13/2015IRN/14/2015 TUR/48/2016.019*
TUR/175/2015.712* ARM/3/2015
IRN/21/2015 IRN/8/2015 IRN/18/2015 IRN/17/2015 IRN/22/2015
IRN/8/2016 TUR/203/2015.827*IRN/11/2016
IRN/12/2016 TUR/305/2015.923* TUR/219/2015.865* TUR/331/2015.923*
IRN/39/2016
100
100
87
0.00 0.04 0.08 0.12
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
11
Israel
Batch: WRLMEG/2017/00043
Date received: 03/07/2017
No. of samples: 2
O (EA-3): 1
A (ASIA/G-VII): 1
Sequences received from the Kimron Veterinary Institute, Israel
Israel continued
on next page
ISA-1
ME-SAPanAsia
FAR-09 PanAsia-2
EA-2
SEA
EA-3
ISA/1/62
UKG/35/2001
IRN/31/200997
IND/53/79Manisa/TUR/69*
TAI/189/87*
86
UGA/3/2002
MAL/1/98
TAN/2/2004
100
100
SUD/6/2012
SUD/2/86ETH/1/2007
ETH/3/2004
EGY/19/2012
SUD/1/2012
SUD/5/2012
SUD/3/2012
SUD/2/2012
ERI/16/2011
ERI/13/2011
ERI/12/2011
ETH/59/2011
ERI/11/2011
ERI/1/2011
ERI/3/2011
ERI/8/2011
ETH/7/2012
ERI/4/2011
ERI/2/2011
100
EGY/1 8/2016
EGY/9/2016EGY/5 /2016
Ismailia 11/Egy/2016*
EGY/ 10/2015EGY/14/2016
EGY/25/2012
87ERI/17/2011
ERI/10/2011
ERI/18/2011
ETH/28/2011
ERI/15/2011
ERI/14/2011
ETH/26/2011
EGY/27/2012
EGY/26/2012
87EGY/ 16/2016
87EGY/ 12/2016
87EGY/ 9/2015
EGY/ 8/2016
Ismailia 8/Egy/2016*
Ismai lia 9/Egy/2016*
Giza 2/Egy/2016*
EGY/13/2015
EGY/1 7/2016
Ismai lia 2/Egy/2016*
Ismai lia 4/Egy/2016*
Ismai lia 3/Egy/2016*
71EGY/7/EGY/4/EGY/
EGY/3/2015
El-Behira 3/Egy/2016*
2016201611/2015
Ismailia 1/Egy/2016*
Cairo 1/Egy/2016*
El-B ehira 2/Egy/2016*
El-B ehira 1/Egy/2016*EGY/14/2015
Isma ilia 5/Egy/2016*
Ismai lia 6/Egy/2016*
EGY/10/2016Giza 1/Egy/2016*
Ismailia 7/Egy/2016*98
99 EGY/11/2016
93
ETH/4/2017
SUD/4/2013
ETH/5/2017
ETH/2/2017
97ETH/3/2017
89PAT/2/2017
89PAT/10/2017
89PAT/5/2017
PAT/7/2017
West Bank/PAT/2017*ISR/8/2017
Ramallah/PAT/2017*
Bani Na’im/PAT/2017 B*
Bani Na’im/PAT/2017 C*
Bani Na’im/PAT/2017 A*
Yatta-Kraisah/PAT/2017*
ISR/3/2017
PAT/9/2017
ISR/4/2017
ISR/1/2017
ISR/2/2017
PAT/1/2017
PAT/4/2017
PAT/6/2017
ISR/6/2017
ISR/7/2017
ISR/5/2017
Ayn al-Sahla/ISR/2017*
86
100
100
100
86
0.00 0.04 0.08
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
12
Israel continued
EURO-SA AFRICA
ASIA
Iran-05
Iran-87 A22 A15 A24G-III
QAZ-11 SIS-10 ARD-07
Iran-96 Iran-99
G-VII
KEN/3/64Cruzeiro/BRA/55*
Bangkok/TAI/60*IRQ/24/64
IRN/2/87TUR/1/2008
IRN/125/201092
IRN/9/2011100
IRN/22/99
SAU/16/95
IRN/1/96
85
BHU/42/2003
IND/40/2000*
99 BHU/27/2003
BHU/41/2002
BHU/8/2003
BHU/6/2003BHU/7/2003BHU/35/2003
91
99
IND/245/2007*
83 IND/417/2007*
IND/413/2007*
IND/407/2007*IND/128/08*
95 84IND/124/2008*
IND/124/08*
IND/438/2008*
BHU/4/2003
10I0ND/360/07*100IND/245/2007*
94 IND/360/2007*
IND/11/2009*IND/13/2009*
100 IND/17/2009*
83
IND/226/2010*
99IND/17/2009*
99IND/9/2009*
97
BAN/GA/Sa-197/2013*IND/256/2012(582)*
73
TUR/1227/2016.750*TUR/1210/2016.750*
TUR/1008/2016.500*
IRN/4/2017
TUR/1225/2016.769*TUR/1218/2016.769*92
TUR/219/2015.865*
TUR/331/2015.923*
TUR/175/2015.712*
TUR/1193/2016.731*
TUR /198/2015.808*
ARM/3/2015
ARM/1/2015IRN/12/2016
TUR/305/2015.923*
IRN/1/2016
IRN/20/2016
IRN/11/2016
IRN/23/2016
100SAU/4/2015
SAU/3/2015
IRN/12/2015
IRN/25/2015
ARM/2/2015
IRN/8/2016
TUR/203/2015.827*
IRN/39/2016
IRN/8/2015
IRN/18/2015
IRN/17/2015
IRN/22/2015
IRN/21/2015
89IRN/13/2015
IRN/14/2015
TUR/48/2016.019*
100SAU/24/2016
SAU/21/2016
SAU/22/2016
100
SAU/21/2015
SAU/7/2015
SAU/16/2015
SAU/15/2015
SAU/14/2015
SAU/17/2015
SAU/5/2015
8S2AU/2/201582 SAU/6/2015
100 SAU/9/2015
SAU/1/2015
PD78/IND/2015*
SAU/15/2016
85 SAU/40/2016
SAU/41/2016
SAU/8/2015
SAU/20/2016100
92
Aramsha/ISR/2017 epith*
87SAU/42/2016
87SAU/19/2016
87SAU/37/2016
Aramsha/ISR/2017 probang*Qela/ISR/2017*
100
98
100
100
74
93
0.00 0.04 0.08 0.12
IRN/27/2015
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
13
Laos
Batch: WRLFMD/2017/00013
Date received: 23/05/2017
No. of samples: 2
O (SEA/Mya-98): 2
ISA-1
ME-SA
SAN-09 QOM-15 BAL-09
TER-08 PanAsia-2
PUN-10ANT-10FAR-09
SEAMya-98
ISA/1/62IRN/18/2010IRN/6/2015
TUR/264/2009*TUR/257/2008*
99
IRN/8/2005IRN/31/2009IRN/88/2009
100
TAI/189/87*PAK/16/2010
SKR/4/2010 MOG/2004*
MYA/7/98
75KOR/1/2010*70
MY/CHA/2010* 33-P/CHA/2010*
GSLX/CHA/2010* VIT/NCVD-9/2010* VIT/NCVD-8/2010*GZ/CHA/2010*
SKR/13/2010
HKN/15/2010HKN/8/2010
72HKN/7/2010HKN/13/2010Yeoncheon/SKR/2010*
80 Yangju/SKR/2010* SKR/8/2011 SKR/7/2010SKR/1/2011
Paju/SKR/2010*87SKR/3/2011
80CHA/31/2010*
BY/CHA/2010* HKN/14/2010HKN/12/2010 HKN/11/2010
74HKN/10/2010HKN/9/2010
JPN/MZ1/2010*DRK/31/2011
VIT/NCVD-20/2010* TAI/22/2009
100 MYA/5/2009 MYA/6/2009
95SKR/6/201095 Andong 1/SKR/2010*
SKR/5/2010
VIT/NCVD-19/2010* VIT/NCVD-18/2010* VIT/NCVD-17/2010*9883
100
MAY/12/2012 MAY/30/2009
MAY/15/2012
MAY/13/2012 MAY/16/2012
MAY/14/2012MAY/10/2012
MAY/17/201294
MAY/6/2012 MAY/11/2012
100
TAI/25/2015MYA/1/2015
TAI/34/2016TAI/1/2017
72
TAI/45/2016 TAI/42/2016 TAI/30/2016 TAI/31/2016
TAI/56/2016
73VIT/15/2016 VIT/17/2016
TAI/26/2016
MYA/4/2017a* TAI/21/2016
TAI/22/2015 TAI/30/2015
87TAI/32/201687 TAI/44/2016 TAI/43/2016
LAO/2/2017 LAO/1/2017
82 LAO/5/2017*
LAO/1/2017R3* TAI/40/2016 TAI/39/2016TAI/48/2016
85 TAI/49/2016 TAI/37/2016
TAI/50/2016 TAI/46/2016
TAI/33/2016 TAI/47/2016 TAI/38/2016
TAI/35/2016 TAI/59/2016 TAI/55/2016
TAI/51/2016
87TAI/41/2016
83
100
89
91
95
97
0.00 0.04 0.08
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
14
Mongolia
Batch: WRLFMD/2017/00010
Date received: 08/05/2017
No. of samples: 16
O (ME-SA/PanAsia): 7
O (SEA/Mya-98): 1
A (ASIA/Sea-97): 2
NVD: 6
Mongolia continued on next
page ISA-1
ME-SA
QOM-15 BAL-09
TER-08SAN-09 PanAsia-2
Ind-2001
dcabKAT-15ANT-10FAR-09
PanAsia
SEA
Cam-94
Mya-98
ISA/1/62
Manisa/TUR/69* IND/R2/75*
IND/53/79IRN/18/2010
IRN/6/201571
IRN/8/2005TUR/257/2008*TUR/264/2009*
100
IRN/31/2009IRN/88/2009
72
NEP/1/2015
90
OMN/7/200196
UAE/4/2008
KUW/3/97
BHU/3/200998
LAO/2/2010 VIT/9/2011 VIT/12/2011 VIT/4/2011
93 VIT/35/2011VIT/34/2011UKG/35/2001
VIT/6/2011 VIT/5/2011VIT/37/2011
VIT/16/2011LAO/3/2012
MOG/7/2017*
MOG/2/2017a* MOG/3/2017a* MOG/5/2017* MOG/8/2017*MOG/10/2017a* MOG/6/2017* MOG/9/2017*
VIT/29/2011
MOG/12/2017 MOG/3/2017
MOG/11/2017MOG/10/2017
MOG/1/2017a* MOG/2/2017
MOG/1/2017
100
93VIT/33/2013 VIT/32/2013
87VIT/12/2013 VIT/11/2013
VIT/51/2013VIT/47/2013VIT/46/2013
VIT/37/2013VIT/40/2013VIT/12/2014VIT/9/2014
VIT/11/2014
MOG/6/2015MOG/3/2014
MOG/1/2014 MOG/5/2014
71MOG/2/2014 MOG/4/2014
VIT/38/2013VIT/13/2013 VIT/15/2013
86CAM/3/2013CAM/2/2013
100
100
87
CAM/3/98TAI/189/87*
MYA/7/98TAI/13/2014
TAI/7/2015TAI/19/2014
MAY/18/2014
MAY/9/2014 MAY/10/2014
TAI/11/2014 MAY/17/2014
TAI/20/2014
VIT/21/2014VIT/27/2014VIT/26/2014TAI/9/2015
99MOG/5/201599MOG/3/201599MOG/1/2015
99MOG/2/2015 MOG/4/2015
MAY/2/2014
VIT/4/2015 VIT/18/2014VIT/13/2014
TAI/10/2014
100
80
77
93
0.00 0.04 0.08
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
15
Mongolia continued
EURO-SA
AFRICA
A24G-IIIG-VII
ASIA
ARD-07 Iran-05FAR-11
Thai-87Iran-96G-VIIIran-87A22
Sea-97
UGA/13/66KEN/3/64
99
Cruzeiro/BRA/55*TUR/1/2008IRN/1/2011
100
IRQ/24/64IRN/2/87
SAU/16/95IRN/1/96
83
TAI/118/87*
TAI/7/2003 TAI/2/97
TAI/1/2011TAI/3/2011
TAI/16/201174
MAY/4/2011TAI/5/2012
95 TAI/8/2012
91TAI 3/12*91TAI/8/2016
98 TAI/4/2012
72
THA 66-1/10*THA 69-6/10*TAI/8/2010
TAI/24/2011
81THA 67-3/10* TAI/7/2010
MAY/2/2011 TAI/9/2011
81 TAI/10/2011
94
75
TAI/20/2016TAI/19/2016TAI/22/2016
100
TAI/23/2016TAI/11/2016TAI/16/2016TAI/13/2016TAI/15/2016
TAI/12/2016
TAI/18/2016 TAI/7/2016 TAI/6/2016 TAI/10/2016
TAI/24/2015 TAI/21/2015 TAI/17/2014 TAI/12/2015 TAI/13/2015 TAI/23/2015
KM/TAW/2015*
TAI/21/2014LAO/1/2015TAI/4/2015TAI/3/2015TAI/5/2015Zabaikalsky/5/RUS/2013*
Zabaikalsky/2/RUS/2014*92
Amur/2/RUS/2013* Amur/4/RUS/2013*
95MOG/12/201395 MOG/11/2013 MOG/13/2013
Zabaikalsky/RUS/2013* KAZ/1/2013*
MYA/3/2015
98MOG/2/201398MOG/4/2013
95MOG/1/20139M4OG/2013*
93 MOG/3/2013MOG/5/2013KAZ/2/2013*
87170208YC/SKR/2017*
SKR/3/2017VIT/16/2016VIT/14/2016
100TAI/9/2016
100 TAI/17/2016 TAI/3/2016
MYA/4/2015 MYA/2/2015
HY/CHA/2013* GDMM-CHA-2013-S* VIT/16/2015
Zabaikalsky/6/RUS/2013*Zabaikalsky/1/RUS/2014*
93
MOG/1/201688MOG/2/2016
90MOG/14/2016*
100 MOG/15/2016* MOG/11/2016*
VIT/26/2012 VIT/25/2012 TAI/15/2012
87VIT/12/201587VIT/13/2015
VIT/1/2016
76 Amur/RUS/2013* Amur/3/RUS/2013*
98
100
99
100
93
0.00 0.04 0.08 0.12
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
16
Myanmar
Batch: WRLFMD/2017/00012
Date received: 23/05/2017
No. of samples: 5
O (ME-SA/Ind-2001d): 3
Asia 1 (ASIA/G-VIII): 1
FMDV-GD: 1
Batch: WRLMEG/2017/00034
Date received: 24/04/2017
No. of sequence: 5
O (ME-SA/Ind-2001d): 4
Asia 1 (ASIA/G-VIII): 1
Myanmar continued on next page
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
17
Myanmar continued
Myanmar continued on next page
SEA ISA-1
ME-SA
FAR-09
TER-08 PanAsia-2BAL-09ANT-10
PanAsia
Ind-2001
cba
d
ISA/1/62TAI/189/87*
Manisa/TUR/69*IRN/31/2009
IRN/8/2005TUR/257/2008*
70
IRN/18/201098
UKG/35/2001IRN/88/200983
KUW/3/97OMN/7/2001
UAE/4/200878
BHU/3/2009SAU/7/2016
77
BAN/LK/Sa-248/2015* NEP/9/2015
97 NEP/10/2015 NEP/12/2015
NEP/11/2015 NEP/4/2016
NEP/17/2016
98 SAU/2/2016 SAU/3/2016
SAU/10/2016
98UAE/4/201698UAE/3/2016
98UAE/5/201696 UAE/2/2016
UAE/1/2016
87 SAU/18/2015 SAU/20/2015
89
NEP/27/2016 NEP/19/2015
NEP/14/2016
95 BHU/8/2016 BHU/9/2016
BHU/10/2016
86 NEP/13/2016 NEP/12/2016
UAE/1/201578 87SAU/19/2015
NEP/35/2016 NEP/37/2016
94
NEP/5/2016
92NEP/25/2016
92NEP/22/2016NEP/23/2016NEP/20/2016NEP/24/2016
NEP/28/2015NEP/30/2016
10N0EP/32/201610N0EP/31/2016
100 NEP/29/2016
84 NEP/11/2016 NEP/10/2016
NEP/6/2016 NEP/17/2015
MYA/5/2017100
BAN/TG/Ba-268/2015*BAN/LK/Sa-249/2015*
80
88NEP/15/201586 NEP/14/2015
NEP/8/2016
95 MUR/1/2016
MUR/24/2016 NEP/7/2016 MYA/3/2016
88 MYA13-2016* MYA12-2016 2*
BAN/SI/Sh-234/2015*
75
MYA/9/2017* MYA/8/2017*
84 BAN/NL/Lo-245/2015* BHU/2/2016
BAN/GKa-236(pig)/2015* XJPS/CHA/2017* NEP/9/2016
MYA/1/2017
MYA/10/2017* -
96SKR/1/201796 170205/SKR/2017* SKR/2/2017
170206/SKR/2017*
71Zabaikalskiy/1/RUS/2016* Zabaikalskiy/2/RUS/2016*Zabaikalskiy/4/RUS/2016*
98 TAI-225-2016R3* TAI-269-2-2016*
Zabaikalskiy/3/RUS/2016* VIT/20/2016
XJBC/CHA/2017*
MYA/11/2017*98
MYA/6/2017*MYA/2/201797
100
97
86
0.00 0.04 0.08
MYA/19/2017*
MYA/17/2017*
MYA/13/2017*
MYA/12/2017*
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
18
Myanmar continued
MYA/14/2017*
G-V
Sindh-08 G-I
G-VIb
G-III
G-VIII
IND/63/72* IND/18/80
YNBS/CHA/58*72
88
PAK/8/2008 AFG/1/2001
100
Shamir/ISR/89*IRN/10/2004
IND/14/95*IND/762/2003*IND/18/2011*
IND175/2007* IND 227/07*
IND 97/08*IND 137/08*
IND 96/08*IND 93/08*IND96/2008*
IND 95/08*
100
IND 121/07*
BAR/8/2009 IND 32/08*
IND78(177)/2011* IND/78/2011*
10086
IND 12/07*IND/341/2008*
10076
IND/155/2010* IND341/2008*
BD BAU ML5 2013* BD BAU ML6 2013*
IND356/2007*
100
BAN JE Mf-02 2012*
100 BAN JE Mf-04 2012*
10B0AN JE Mf-01 2012*
10B0AN JE Mf-06 2012* BAN JE Mf-05 2012*100
76
IND/148/2011* IND/248/2009*
100 BAN JE Mf-03 2012*
IND148(326)/2011*IND148(323)/2011*IND148(330)/2011*
IND148(322)/2011* IND148(324)/2011*
IND148(327)/2011* IND148(331)/2011*
100
IND/65/2010*IND65(140)/2010*
99
IND/327/2009* IND327/2009*
IND205(508)/2010* IND/509/2010* IND/205/2010* IND/787/2009*
100
IND285(640)/2012* IND68(128)/2012*IND/68/2012*
IND/285/2012*100
76
IND157(336)/2013*
IND403(826)/2012* IND131(255)/2012*
IND288(643)/2012* IND/291/2012*
IND109(208)/2012* IND163(334)/2012*
IND163(333)/2012* IND162(331)/2012*
86 IND303(658)/2012* IND/303/2012*
IND411(846)/2012*IND411(845)/2012*
88
BAN GA Sr-187 2013* BD SI 2 2013*
IND/292/2012* IND/294/2012*
79IND413(852)/2012*IND400(822)/2012*
78IND120(225)/2012* IND/120/2012*
IND/16/2012* IND15(24)/2012* IND119(223)/2012* IND/283/2012* IND118(222)/2012* IND/118/2012* IND/121/2012*IND/305/2012*
IND156(335)/2013*IND/115/2012* IND/119/2012* IND119(224)/2012* IND/114/2012* IND114(214)/2012* IND/300/2012* IND300(655)/2012*
IND115(217)/2012*
IND/306/2012* IND/288/2012*
MYA/3/201710093
90
85
99
71
98
0.00 0.04 0.08
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
19
Palestinian Autonomous Territories
Batch: WRLMEG/2017/00044
Date received: 03/07/2017
No. of samples: 2
O (EA-3): 5
Sequences received from the
Kimron Veterinary Institute, Israel
ISA-1
ME-SAPanAsia
FAR-09 PanAsia-2
SEA
EA-2
EA-3
ISA/1/62
UKG/35/2001 IRN/31/2009
97
IND/53/79Manisa/TUR/69*
TAI/189/87*
86
MAL/1/98UGA/3/2002
TAN/2/2004
100
ETH/1/2007
ETH/3/200499
SUD/6/2012SUD/1/2012SUD/2/2012
SUD/2/86
SUD/5/2012
EGY/19/2012 SUD/3/2012
ERI/11/2011 ERI/16/2011 ERI/3/2011 ETH/59/2011 ERI/13/2011 ERI/12/2011 ERI/2/2011 ERI/1/2011 ERI/8/2011
ETH/28/2011ERI/14/2011ERI/15/2011ETH/26/2011ERI/18/2011EGY/27/2012EGY/26/2012
100
EGY/18/2016 EGY/14/2016 EGY/5/2016Ismailia 11/Egy/2016*
EGY/25/2012
Ismailia 9/Egy/2016* EGY/13/2015 EGY/9/2016
87EGY/16/201687EGY/9/2015
87EGY/12/2016 EGY/8/2016
Ismailia 8/Egy/2016*
Ismailia 5/Egy/2016* Ismailia 6/Egy/2016* EGY/17/2016Ismailia 2/Egy/2016*Ismailia 3/Egy/2016*Ismailia 4/Egy/2016*EGY/10/2015
Giza 2/Egy/2016*
71EGY/7/EGY/4/EGY/
EGY/3/2015
El-Behira 3/Egy/2016* 2016201611/2015
Cairo 1/Egy/2016* El-Behira 2/Egy/2016* El-Behira 1/Egy/2016*
EGY/14/2015
Ismailia 1/Egy/2016*
EGY/11/2016EGY/10/2016
Ismailia 7/Egy/2016* Giza 1/Egy/2016*
98
99
95
ETH/2/2017 SUD/4/2013
73ETH/3/2017
73ETH/5/201797 ETH/4/2017
90PAT/2/2017
90PAT/5/201790PAT/10/2017 PAT/7/2017
West Bank/PAT/2017*ISR/2/2017
Ramallah/PAT/2017* Bani Na’im/PAT/2017 A* Bani Na’im/PAT/2017 B* Bani Na’im/PAT/2017 C*
Yatta-Kraisah/PAT/2017* Ayn al-Sahla/ISR/2017* PAT/1/2017ISR/3/2017ISR/5/2017PAT/6/2017PAT/4/2017ISR/1/2017PAT/9/2017ISR/7/2017ISR/4/2017ISR/8/2017ISR/6/2017
86
100
100
100
85
0.00 0.04 0.08
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
20
Thailand
Batch: WRLFMD/2017/00011
Date received: 23/05/2017
No. of samples: 28
O (SEA/Mya-98): 18
A (ASIA/Sea-97): 10
Thailand continued on next page
ISA-1
ME-SAPanAsia-2
SAN-09 TER-08 QOM-15 BAL-09
PUN-10ANT-10FAR-09
PanAsia
SEA
Cam-94
Mya-98
ISA/1/62IRN/18/2010IRN/6/2015
TUR/257/2008*TUR/264/2009*
99
IRN/8/2005IRN/31/2009IRN/88/2009PAK/16/2010UKG/35/2001
100
IND/R2/75*
77
CAM/3/98
MOG/2004* MYA/7/98
TAI/189/87*
MY/CHA/2010* VIT/NCVD-9/2010*
HKN/7/2010
SKR/8/2011 HKN/15/2010 HKN/12/2010 HKN/9/2010 HKN/11/2010 HKN/10/2010
SKR/3/2011
88Yeoncheon/SKR/2010*
SKR/4/2010
92Paju/SKR/2010*
33-P/CHA/2010*
80KOR/1/2010*
MYA/5/2009100 MYA/6/2009
VIT/NCVD-19/2010* MAY/30/2009
99 VIT/NCVD-20/2010*82
100
MAY/15/2012 TAI/22/2009
MAY/13/2012 MAY/17/2012 MAY/11/2012 MAY/14/2012
94MAY/16/2012
MAY/6/2012 MAY/12/2012 MAY/10/2012
100
TAI/25/2015MYA/1/2015
TAI/21/2016 TAI/22/2015
TAI/30/2015
MYA/4/2017a*
LAO/2/2017 TAI/26/2016
TAI/30/2016 TAI/31/2016
TAI/59/2016 TAI/39/2016
TAI/49/2016
85TAI/37/2016 TAI/48/2016
TAI/50/2016 TAI/46/2016
TAI/40/2016 TAI/47/2016 TAI/38/2016 TAI/35/2016 TAI/33/2016
LAO/1/2017R3*
84 LAO/5/2017* LAO/1/2017
TAI/42/2016
87TAI/43/201687TAI/44/2016 TAI/32/2016
80VIT/17/2016
VIT/15/2016 TAI/55/2016
TAI/51/2016 TAI/45/2016
87TAI/41/2016
TAI/56/2016
84
TAI/34/2016TAI/1/201779
100
93
89
99
83
0.00 0.04 0.08
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
21
Thailand continued
TAI/60/2016
TAI/57/2016
TAI/52/2016
TAI/3/2017TAI/2/2017
TAI/4/2017TAI/54/2016
TAI/58/2016TAI/5/2017
TAI/53/2016
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
22
2.2. AFRICA
Algeria
Batch: WRLFMD/2017/00006
Date received: 18/04/2017
No. of samples: 3
A (AFRICA/G-IV): 3
* 5 sequences from the same locations as ALG 1/2017 and ALG 2/2017 for analysis were also received
ASIA
EURO-SA
AFRICA
G-V G-VI G-II G-III G-I G-VII A24 A5 A12 A22Sea-97
G-IV
TAI/2/97IRQ/24/64
89
UKG/119/32Allier/FRA/60*
Cruzeiro/BRA/55*98
UGA/13/66
KEN/3/64 KEN/42/66
EGY/1/72GHA/16/73
NGR/2/73SUD/2/84SUD/1/85
97
SUD/1/8195
SUD/3/7796
SUD/12/2011 SUD/13/2011 SUD/7/2011 SUD/6/2011 SUD/1/2011
EGY/1/2012
100 EGY/42/2012 EGY/30/201299
99 EGY/18/2012 EGY/20/2012
100
SUD/3/2006ERI/1/2006
98
100
ERI/3/97ERI/3/98ERI/2/98
100100
CAR/P22/2000 fke/066/08*CAR/36/2005
CAR/116/2005100
74
CAR/P19/2000 mfa/057/01*
CAR/14/2000CAR/13/2000CAR/12/2000CAR/15/2000100
MAI/12/2006MAI/4/2004
100
NIG/15/2009a* NIG/7/2009* NIG/20/2009* NIG/9/2009* NIG/13/2009* NIG/21/2009* NIG/8/2009* NIG/5/2009* NIG/12/2009* NIG/10/2009*
TOG/9/2005
NIG/11/2009* NIG/14/2009* NIG/6/2009* NIG/17/2009* NIG/19/2009* NIG/18/2009*
NIG/2/2009*NIG/4/2009*NIG/1/2009*
NIG/3/2009a*NIG/16/2009*
100
CAR/58/2012
CAR/60/2012 CAR/61/2012100
97
100
NIG/3/201390 75NIG/1/13a*
93 NIG/12/2012
NIG/2/13a*NIG/3/2009
NIG/8/201378NIG/6/2013
NIG/7/201390
95
NIG/36/2009NIG/38/2009
NIG/39/2009
100
NIG/10/2012 NIG/8/2012
100
NIG/9/201289 NIG/2/2011
100CAR/11/2013
100CAR/4/2013 CAR/36/2013 CAR/10/2013
100
91
NIG/02/15*NIG/01/15*
NIG/10/15*NIG/04/15* NIG/06/15*
87NIG/05/15*NIG/07/15*
87
ALG/3/2017
ALG/IZSLER/99572/1/2017*ALG/IZSLER/99572/2/2017*ALG/IZSLER/99572/3/2017*
ALG/1/2017
ALG/IZSLER/99572/4/2017*83
ALG/2/201783ALG/IZSLER/99572/5/2017*
95
100
100
85
100
96
0.00 0.04 0.08 0.12
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
23
Ethiopia
Batch: WRLFMD/2017/00007
Date received: 11/04/2017
No. of samples: 27
O (EA-3): 4
O (EA-4): 13
FMDV-GD: 3
NVD: 7
Batch: WRLFMD/2017/00009
Date received: 15/05/2017
No. of samples: 54
O (EA-4): 14
FMDV-GD: 19
NVD: 21
ETH/13/2016
EA-3 ISA-1
EA-3
EA-3
EA-2
WA
EA-3
ME-SA
ab Ind-2001a
PanAsia
EA-1
SEA
EA-4
ISA/1/62ETH/2/2006
YEM/48/2004 YEM/4/95
YEM/6/83
YEM/37/2009KEN/3/98
SOM/2/2007
ETH/1/2007
ETH/3/200484
78
SUD/2/86
100 SUD/3/89
SUD/4/89100
MAL/1/98UGA/3/2002
TAN/2/2004
100
Ismailia 5/Egy/2016*
CIV/8/99
EGY/9/2016 EGY/14/2015
Ismailia 11/Egy/2016* EGY/13/2015Giza 2/Egy/2016* EGY/14/2016
EGY/5/2016
100
95
PAT/1/2017 SUD/4/2013
87 EGY/7/2016EGY/4/2016EGY/17/2016
88ISR/5/20178888ISR/6/2017
88ISR/4/201788ISR/2/201788PAT/6/201788ISR/8/201788PAT/4/201788ISR/3/201788ISR/1/201788ISR/7/2017
71PAT/2/201783PAT/10/2017
97 PAT/7/2017 PAT/9/2017
ETH/3/2017ETH/4/2017
97 ETH/5/2017 EETH/2/2017
71PAT/5/2017100
100
IND/53/79KUW/3/97
OMN/7/2001100
NEP/121/90100
Manisa/TUR/69*
UKG/35/2001
TAI/189/87*
BUN/10/86 K83/79*
100
ETH/58/2005ETH/59/2005
10E0TH/60/2005
100
95
96ETH/14/2013
96ETH/15/2013 ETH/12/2013
ETH/4/2013 UGA/17/98
ETH/8/2013100ETH/9/2013
78 96ETH/13/2013
ETH/1/2016
100
KEN/100/2010
89
ETH/8/2016
ETH/12/201690 ETH/9/2016
ETH/7/2016
97 ETH/18/2016 ETH/11/2016
ETH/2/2016ETH/6/2016
98
ETH/3/2016ETH/4/2016
100
100
94
99
0.00 0.04 0.08
ETH/22/2016ETH/16/2016
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
24
Ethiopia continued
ISA-1
ME-SA
a Ind-2001
PanAsia
SEA
EA-1
EA-3
EA-4
ISA/1/62
91
UKG/35/2001
NEP/121/90
KUW/3/97
83
99
YEM/8/85
Amursk/RUS/2004*
YEM/4/80
83
BUN/1/84
TAI/189/87*
Manisa/TUR/69*
BUN/10/86100
K83/79*100
K103/82*K40/84*
100 K40/84*
100
85
ETH/1/2007ETH/3/2004
92
KEN/3/98
KEN/7/98
KEN/1/99
84 YEM/28/2003
YEM/1/2004
YEM/22/2003
97
100
YEM/24/2009
YEM/4/95
YEM/48/2004
100ETH/31/2008
ETH/32/200890
YEM/8/2008
10Y0EM/5/2008
100 YEM/6/2008
89
YEM/36/2009YEM/37/2009
100
100
SOM/2/2007SOM/1/2007
100
ETH/1/79ETH/11/2005
100
YEM/3/7487
84
SUD/7/89
96SUD/3/89
SUD/4/89
91SUD/5/89
SUD/6/89
YEM/6/83
SUD/2/86100
72
ETH/2/2006
SUD/2/89
100ETH/58/2005
ETH/60/2005
ETH/59/2005
100
99
95ETH/14/2013
100 ETH/9/2013
ETH/8/2013
95ETH/12/2013
80 95 ETH/13/2013
ETH/15/2013
ETH/4/2013
UGA/17/98
100
ETH/16/2016
ETH/13/2016
ETH/6/2016
KEN/100/2010
ETH/1/2016
96ETH/22/2016ETH/30/2016ETH/51/2016ETH/49/2016ETH/34/2016
ETH/36/201696ETH/35/2016
ETH/3/2016ETH/4/2016
100
ETH/7/2016
84 ETH/8/2016
89 ETH/18/2016
ETH/11/201699ETH/12/2016
ETH/9/2016
ETH/25/2016
ETH/73/2016
ETH/29/2016
93ETH/37/2016
ETH/48/2016
ETH/2/2016
ETH/61/2016
ETH/50/2016
ETH/32/2016
100
100
88
93
0.00 0.04 0.08
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
25
3. Vaccine matching
During this reporting period vaccine matching has been undertaken for 4 FMD virus field strains: serotype O (n=2) and serotype A (n=2). These are samples from Ethiopia and Iran.
For individual data see Annex 1, section 4.3 (Antigenic Characterisation).
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
26
4. Annex 1
4.1. Summary of Submissions
Table 2: Summary of samples collected and received to WRLFMD (April to June 2017)
Country No of
samples
Virus isolation in cell culture/ELISA RT-PCR for FMD (or SVD)
virus (where appropriate)
FMD virus serotypes
No
Vir
us
Dete
cte
d
O A C SAT
1 SAT
2 SAT
3 ASIA
-1 Positive Negative
ALGERIA 3 - 3 - - - - - - 3 -
CAMBODIA 4 - - - - - - - - - -
ETHIOPIA 81 31 - - - - - - 50 52 29
IRAN 24 9 9 - - - - - 6 22 2
LAOS 2 - - - - - - - 2 2 -
MONGOLIA 16 8 2 - - - - - 6 10 6
MYANMAR 5 3 - - - - - - 2 5 -
THAILAND 28 18 10 - - - - - - 28 -
TOTAL 163 69 24 - - - - - 66 122 37
Abbreviations used in table
VI / ELISA FMD (or SVD) virus serotype identified following virus isolation in cell culture and antigen detection ELISA
FMD Foot-and-mouth disease
SVD Swine vesicular disease
NVD No FMD, SVD or vesicular stomatitis virus detected
NT Not tested
rRT-PCR Real-time reverse transcription polymerase chain reaction for FMD (or SVD) viral genome
4.2. Clinical Samples
Table 3: Clinical sample diagnostics made by the WRLFMD® April to June 2017
Country WRL for FMD
Sample Identification
Animal Date of
Collection
Results
VI/ELISA RT-PCR Final report
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
27
Country WRL for FMD
Sample Identification
Animal Date of
Collection
Results
VI/ELISA RT-PCR Final report
ALGERIA ALG 1/2017 CATTLE 09-Apr-17 A POS A ALG 2/2017 CATTLE 09-Apr-17 A POS A ALG 3/2017 CATTLE 11-Apr-17 A POS A
CAMBODIA
CAM 1/2016 Awaiting information
from sender 02-Dec-16 Pending Pending Pending
CAM 2/2016 Awaiting information
from sender 02-Dec-16 Pending Pending Pending
CAM 3/2016 Awaiting information
from sender 02-Dec-16 Pending Pending Pending
CAM 4/2016 Awaiting information
from sender 02-Dec-16 Pending Pending Pending
ETHIOPIA
ETH 2/2016 CATTLE 10-Feb-16 O POS O ETH 3/2016 CATTLE 23-Feb-16 O NEG O ETH 4/2016 CATTLE 04-Aug-16 O POS O ETH 5/2016 CATTLE 05-Aug-16 NEG POS FMDV GD ETH 6/2016 CATTLE 03-Sep-16 O POS O ETH 7/2016 CATTLE 05-Sep-16 O POS O ETH 8/2016 CATTLE 31-Oct-16 O POS O ETH 9/2016 CATTLE 31-Oct-16 NEG NEG NVD ETH 10/2016 CATTLE 31-Oct-16 O POS O ETH 11/2016 CATTLE 11-Nov-16 O POS O ETH 12/2016 CATTLE 11-Nov-16 O POS O ETH 13/2016 CATTLE 18-Nov-16 NEG NEG NVD ETH 14/2016 CATTLE 18-Nov-16 NEG POS FMDV GD ETH 15/2016 CATTLE 20-Nov-16 O POS O ETH 16/2016 CATTLE 27-Nov-16 NEG NEG NVD ETH 17/2016 CATTLE 29-Nov-16 O POS O ETH 18/2016 CATTLE 31-Nov-16 NEG NEG NVD ETH 19/2016 CATTLE 18-Dec-16 NEG NEG NVD ETH 20/2016 CATTLE 18-Dec-16 NEG NEG NVD ETH 21/2016 CATTLE 18-Dec-16 O POS O ETH 22/2016 CATTLE 27-Dec-16 NEG NEG NVD ETH 23/2016 CATTLE 31-Dec-16 NEG POS FMDV GD ETH 24/2016 BOVINE 03-Jan-16 NEG POS FMDV GD ETH 25/2016 BOVINE 03-Jan-16 O POS O ETH 26/2016 BOVINE 27-Jan-16 NEG POS FMDV GD ETH 27/2016 BOVINE 27-Jan-16 NEG POS FMDV GD ETH 28/2016 BOVINE 03-Mar-16 NEG POS FMDV GD ETH 29/2016 BOVINE 03-Mar-16 O POS O ETH 30/2016 BOVINE 16-Mar-16 O POS O ETH 31/2016 BOVINE 16-Mar-16 NEG POS FMDV GD ETH 32/2016 BOVINE 12-Apr-16 O POS O ETH 33/2016 BOVINE 12-Apr-16 NEG POS FMDV GD ETH 34/2016 BOVINE 27-Jun-16 O POS O ETH 35/2016 BOVINE 27-Jun-16 O POS O ETH 36/2016 BOVINE 08-Aug-16 O POS O ETH 37/2016 BOVINE 08-Aug-16 O POS O ETH 38/2016 BOVINE 11-Aug-16 NEG POS FMDV GD ETH 39/2016 BOVINE 11-Aug-16 NEG NEG NVD ETH 40/2016 BOVINE 12-Sep-16 NEG NEG NVD ETH 41/2016 BOVINE 12-Sep-16 NEG NEG NVD ETH 42/2016 BOVINE 02-Oct-16 NEG NEG NVD ETH 43/2016 BOVINE 02-Oct-16 NEG NEG NVD ETH 44/2016 BOVINE 12-Oct-16 NEG POS FMDV GD
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
28
Country WRL for FMD
Sample Identification
Animal Date of
Collection
Results
VI/ELISA RT-PCR Final report
ETH 45/2016 BOVINE 12-Oct-16 NEG NEG NVD ETH 46/2016 BOVINE 12-Oct-16 NEG POS FMDV GD ETH 47/2016 BOVINE 12-Oct-16 NEG NEG NVD ETH 48/2016 BOVINE 13-Oct-16 O POS O ETH 49/2016 BOVINE 13-Oct-16 O POS O ETH 50/2016 BOVINE 21-Oct-16 O POS O ETH 51/2016 BOVINE 21-Oct-16 O POS O ETH 52/2016 BOVINE 28-Oct-16 NEG POS FMDV GD ETH 53/2016 BOVINE 28-Oct-16 NEG NEG NVD ETH 54/2016 BOVINE 28-Oct-16 NEG POS FMDV GD ETH 55/2016 BOVINE 28-Oct-16 NEG POS FMDV GD ETH 56/2016 BOVINE 11-Nov-16 NEG POS FMDV GD ETH 57/2016 BOVINE 11-Nov-16 NEG NEG NVD ETH 58/2016 BOVINE 11-Nov-16 NEG NEG NVD ETH 59/2016 BOVINE 11-Nov-16 NEG POS FMDV GD ETH 60/2016 BOVINE 23-Nov-16 NEG POS FMDV GD ETH 61/2016 BOVINE 23-Nov-16 O POS O ETH 62/2016 BOVINE 13-Dec-16 NEG NEG NVD ETH 63/2016 BOVINE 13-Dec-16 NEG NEG NVD ETH 64/2016 BOVINE 18-Dec-16 NEG POS FMDV GD ETH 65/2016 BOVINE 18-Dec-16 NEG NEG NVD ETH 66/2016 BOVINE 19-Dec-16 NEG NEG NVD ETH 67/2016 BOVINE 19-Dec-16 NEG NEG NVD ETH 68/2016 BOVINE 19-Dec-16 NEG NEG NVD ETH 69/2016 BOVINE 19-Dec-16 NEG POS FMDV GD ETH 70/2016 BOVINE 20-Dec-16 NEG POS FMDV GD ETH 71/2016 BOVINE 20-Dec-16 NEG NEG NVD ETH 72/2016 BOVINE 20-Dec-16 NEG NEG NVD
ETH 73/2016 BOVINE 20-Dec-16 O POS O
ETH 74/2016 BOVINE 27-Dec-16 NEG NEG NVD ETH 75/2016 BOVINE 27-Dec-16 NEG NEG NVD ETH 1/2017 CATTLE 18-Mar-17 O POS O ETH 2/2017 CATTLE 18-Mar-17 O POS O ETH 3/2017 CATTLE 18-Mar-17 O POS O ETH 4/2017 CATTLE 18-Mar-17 O POS O ETH 5/2017 CATTLE 18-Mar-17 O POS O ETH 6/2017 BOVINE 01-Apr-17 NEG POS FMDV GD ETH 7/2017 BOVINE 01-Apr-17 NEG NEG NVD
IRAN
IRN 30/2016 SHEEP 21-Oct-16 NEG NEG NVD IRN 31/2016 CATTLE 14-Nov-16 O POS O IRN 32/2016 CATTLE 28-Nov-16 NEG POS FMDV GD IRN 33/2016 SHEEP 30-Nov-16 NEG NEG NVD IRN 34/2016 CATTLE 06-Dec-16 A POS A IRN 35/2016 CATTLE 14-Dec-16 O POS O IRN 36/2016 SHEEP 22-Dec-16 O POS O IRN 37/2016 CATTLE 24-Dec-16 O POS O IRN 38/2016 SHEEP 26-Dec-16 NEG POS FMDV GD IRN 39/2016 CATTLE 30-Dec-16 A POS A IRN 1/2017 CATTLE 01-Jan-17 NEG POS FMDV GD IRN 2/2017 CATTLE 07-Jan-17 A POS A IRN 3/2017 SHEEP 07-Jan-17 O POS O IRN 4/2017 CATTLE 11-Jan-17 A POS A IRN 5/2017 CATTLE 12-Jan-17 O POS O
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
29
Country WRL for FMD
Sample Identification
Animal Date of
Collection
Results
VI/ELISA RT-PCR Final report
IRN 6/2017 SHEEP 25-Jan-17 A POS A IRN 7/2017 CATTLE 31-Jan-17 A POS A IRN 8/2017 CATTLE 02-Feb-17 O POS O IRN 9/2017 CATTLE 15-Feb-17 A POS A IRN 10/2017 CATTLE 20-Feb-17 A POS A IRN 11/2017 CATTLE 20-Feb-17 O POS O IRN 12/2017 CATTLE 23-Feb-17 O POS O IRN 13/2017 SHEEP 25-Feb-17 A POS A IRN 14/2017 CATTLE 25-Feb-17 NEG POS FMDV GD
LAOS LAO 1/2017 CATTLE 30-Jan-17 NEG POS FMDV GD LAO 2/2017 CATTLE 30-Jan-17 NEG POS FMDV GD
MONGOLIA
MOG 5/2015 CATTLE 03-Mar-15 O POS O MOG 6/2015 CATTLE 12-May-15 O POS O MOG 1/2016 CATTLE 29-Aug-16 A POS A MOG 2/2016 SHEEP 20-Sep-16 A POS A MOG 1/2017 CATTLE 28-Jan-17 O POS O MOG 2/2017 CATTLE 28-Jan-17 O POS O MOG 3/2017 CATTLE 31-Jan-17 O POS O MOG 4/2017 CATTLE 09-Feb-17 NEG NEG NVD MOG 5/2017 CATTLE 20-Feb-17 NEG NEG NVD MOG 6/2017 CATTLE 20-Feb-17 NEG NEG NVD MOG 7/2017 CATTLE 20-Feb-17 NEG NEG NVD MOG 8/2017 CATTLE 23-Feb-17 NEG NEG NVD MOG 9/2017 CATTLE 23-Feb-17 NEG NEG NVD MOG 10/2017 CATTLE 23-Mar-17 O POS O MOG 11/2017 CATTLE 23-Mar-17 O POS O MOG 12/2017 CATTLE 03-Apr-17 O POS O
MYANMAR
MYA 1/2017 CATTLE 27-Jan-17 O POS O MYA 2/2017 CATTLE 27-Jan-17 O POS O MYA 3/2017 CATTLE 08-Apr-17 NEG POS FMDV GD MYA 4/2017 CATTLE 08-Apr-17 NEG POS FMDV GD MYA 5/2017 CATTLE 08-Apr-17 O POS O
THAILAND
TAI 38/2016 CATTLE 03-Aug-16 O POS O
TAI 39/2016 CATTLE 03-Aug-16 O POS O
TAI 40/2016 CATTLE 09-Aug-16 O POS O
TAI 41/2016 CATTLE 09-Aug-16 O POS O
TAI 42/2016 CATTLE 09-Aug-16 O POS O
TAI 43/2016 CATTLE 09-Aug-16 O POS O
TAI 44/2016 CATTLE 09-Aug-16 O POS O
TAI 45/2016 CATTLE 15-Aug-16 O POS O
TAI 46/2016 CATTLE 22-Aug-16 O POS O
TAI 47/2016 CATTLE 26-Aug-16 O POS O
TAI 48/2016 CATTLE 29-Aug-16 O POS O
TAI 49/2016 CATTLE 01-Sep-16 O POS O
TAI 50/2016 CATTLE 02-Sep-16 O POS O
TAI 51/2016 CATTLE 02-Sep-16 O POS O
TAI 52/2016 CATTLE 04-Nov-16 A POS A
TAI 53/2016 CATTLE 08-Nov-16 A POS A
TAI 54/2016 CATTLE 11-Nov-16 A POS A
TAI 55/2016 CATTLE 28-Nov-16 O POS O
TAI 56/2016 CATTLE 29-Nov-16 O POS O
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
30
Country WRL for FMD
Sample Identification
Animal Date of
Collection
Results
VI/ELISA RT-PCR Final report
TAI 57/2016 CATTLE 29-Nov-16 A POS A
TAI 58/2016 CATTLE 30-Nov-16 A POS A
TAI 59/2016 CATTLE 30-Nov-16 O POS O
TAI 60/2016 CATTLE 30-Nov-16 A POS A
TAI 1/2017 SWINE 10-Jan-17 O POS O
TAI 2/2017 CATTLE 11-Jan-17 A POS A
TAI 3/2017 CATTLE 13-Jan-17 A POS A
TAI 4/2017 CATTLE 19-Jan-17 A POS A
TAI 5/2017 CATTLE 03-Feb-17 A POS A
Abbreviations used in table
FMD(V) Foot-and-mouth disease (virus)
FMDV GD Genome detected
FMDV NGD Genome not detected (samples submitted in Trizol, only rRT-PCR carried out)
VI/ELISA FMDV serotype identified following virus isolation in cell culture and antigen ELISA
rRT-PCR Real-time reverse transcription polymerase chain reaction on epithelial suspension for FMD (or SVD) viral genome
NVD No foot-and-mouth disease, swine vesicular disease or vesicular stomatitis virus detected
NT Not tested
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
31
4.3. Antigenic Characterisation
Antigenic characterisation of FMD field isolates by matching with vaccine strains by 2dmVNT from April to June 2017.
Table 4: Vaccine matching studies for O FMDV by VNT
Str
ain
Sero
typ
e
To
po
typ
e
Str
ain
O 3
039
O1 M
an
isa
O/T
UR
/5/2
009
ETH/2/2017 O EA-3 n/d N N Y
ETH/11/2016 O EA-4 n/d N N Y
Table 5: Vaccine matching studies for A FMDV by VNT
Str
ain
Se
roty
pe
To
po
typ
e
Str
ain
A/IR
N/0
5
A/T
UR
/20
/06
A22
IR
AQ
A T
UR
11
A T
UR
14
A C
RU
Z B
VS
ALG/2/2017 A AFRICA G-IV N N B n/d n/d N
ALG/3/2017 A AFRICA G-IV N N B n/d n/d N
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
32
Abbreviations used in tables
M
Vaccine Match
r1 = > 0.3. Suggests that there is a close relationship between field isolate and vaccine strain. A potent vaccine containing the vaccine strain is likely to confer protection.
N
No Vaccine Match
r1 = < 0.3. Suggests that the field isolate is so different from the vaccine strain that the vaccine is unlikely to protect
B
Borderline
Any r1 values between 0.28 to 0.32
NT
Not tested against this vaccine
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
33
5. Annex 2
Recent FMD Publications (April to June 2016) cited by Web of Science (Pirbright Institute papers and authors are highlighted in BOLD AND GREY)
1. Abd El-Rahim, I.H.A., A.H. Asghar, A.M. Mohamed, and S.M. Fat'hi (2016). The impact of importation of live ruminants on the epizootiology of Foot and mouth disease in Saudi Arabia. Revue scientifique et technique (International Office of Epizootics), 35(3): 769-778.
2. Ahmed, A., A. Latif, R. Zahra, A.B. Zahur, U. Farooq, A. Ullah, M. Abubakar, A. Jamil, and M. Afzal (2017). Current appraisal of the suitability of Foot-and-mouth disease strains in two commonly used commercial vaccines for control of FMD in Pakistan. Journal of Animal and Plant Sciences, 27(2): 446-450.
3. Amjad, K., M.H. Mushtaq, A. Mansur-ud-Din, F. Zahida, and K. Asghar (2017). Seasonal trends in seroprevalence of FMD in bovines under different environmental conditions in rural KPK, Pakistan. Pakistan Veterinary Journal, 37(1): 55-58.
4. Arzt, J., B. Brito, S.J. Pauszek, E.J. Hartwig, G.R. Smoliga, L.T. Vu, P.P. Vu, C. Stenfeldt, L.L. Rodriguez, N.T. Long, and D.H. Dung (2017). Genome Sequence of Foot-and-Mouth Disease Virus Serotype O Lineage Ind-2001d Collected in Vietnam in 2015. Genome Announcements, 5(18).
5. Arzt, J., J.M. Pacheco, C. Stenfeldt, and L.L. Rodriguez (2017). Pathogenesis of virulent and attenuated Foot-and-mouth disease virus in cattle. Virology Journal, 14(1): 89-89.
6. Bahar e, M., A. Muhammad, A. Sibtain, A. Muhammad, M.A. Ashraf, U.H. Khan, F. Ahad, and W. Abdul (2016). Experimental trials of Foot-and-mouth disease vaccines with different vegetable oil adjuvants in goats under field conditions. Pakistan Journal of Life and Social Sciences, 14(3): 178-182.
7. Barrette, R.W., J.M. Rowland, F.R. Grau, and M.T. McLntosh (2017). Development of a Feature and Template-Assisted Assembler and Application to the Analysis of a Foot-and-Mouth Disease Virus Genotyping Microarray. Plos One, 12(1).
8. Bohorquez, J.A., S. Defaus, S. Munoz-Gonzalez, M. Perez-Simo, R. Rosell, L. Fraile, F. Sobrino, D. Andreu, and L. Ganges (2017). A bivalent dendrimeric peptide bearing a T-cell epitope from Foot-and-mouth disease virus protein 3A improves humoral response against Classical swine fever virus. Virus Research, 238: 8-12.
9. Boklund, A., S. Mortensen, M.H. Johansen, and T. Halasa (2017). Resource Estimations in Contingency Planning for Foot-and-Mouth Disease. Frontiers in Veterinary Science, 4: 64-64.
10. Bouguedour, R. and A. Ripani (2016). Review of the foot and mouth disease situation in North Africa and the risk of introducing the disease into Europe. Revue scientifique et technique (International Office of Epizootics), 35(3): 757-768.
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
34
11. Bown, C.P. and J.A. Hillman (2017). Foot-and-Mouth Disease and Argentina's Beef Exports: The WTO's US-Animals Dispute. World Trade Review, 16(2): 253-277.
12. Brito, B., S.J. Pauszek, M. Eschbaumer, C. Stenfeldt, H.C. de Carvalho Ferreira, L.T. Vu, N.T. Phuong, B.H. Hoang, N.D. Tho, P.V. Dong, P.Q. Minh, N.T. Long, D.P. King, N.J. Knowles, D.H. Dung, L.L. Rodriguez, and J. Arzt (2017). Phylodynamics of Foot-and-mouth disease virus O/PanAsia in Vietnam 2010-2014. Veterinary Research, 48(1): 24-24.
13. Byoungjuchoi, 김희진, 오세은, and 안세혁 (2017). Real-time Monitoring
Method of Cattle’s Temperature for FMD Prevention and Its Case Studies. Journal of Korean Institute of Information Technology, 15(5): 141-150.
14. Cairns, A., T. Tolhurst, K. Poon, A.P. Ker, S. Duff, D. Jacques, and L. Yang (2017). The economic impact of a Foot-and-mouth disease outbreak for Ontario's beef sector. Canadian Journal of Agricultural Economics, 65(1): 159-183.
15. Cha, C.-N., E.-K. Park, C.-Y. Yoo, S. Kim, Y.W. Yun, and H.-J. Lee (2017). Blood parameter changes in Korean traditional calves and pigs after foot-and-mouth disease vaccination. Korean Journal of Veterinary Research, 57(1): 43-45.
16. Chen, Z., S. Zhang, Z. Li, G. Ma, and Z. Su (2017). Construction of a stable w/o nano-emulsion as a potential adjuvant for Foot-and-mouth disease virus vaccine. Artificial Cells Nanomedicine and Biotechnology, 45(5): 897-906.
17. Countryman, A.M. and A.D. Hagerman (2017). Retrospective Economic Analysis of Foot and Mouth Disease Eradication in the Latin American Beef Sector. Agribusiness, 33(2): 257-273.
18. de la Higuera, I., C. Ferrer-Orta, A.I. de Avila, C. Perales, M. Sierra, K. Singh, S.G. Sarafianos, Y. Dehouck, U. Bastolla, N. Verdaguer, and E. Domingo (2017). Molecular and Functional Bases of Selection against a Mutation Bias in an RNA Virus. Genome Biology and Evolution, 9(5): 1212-1228.
19. Dill, V., M. Beer, and B. Hoffmann (2017). Simple, quick and cost-efficient: A universal RT-PCR and sequencing strategy for genomic characterisation of Foot-and-mouth disease viruses. Journal of Virological Methods, 246: 58-64.
20. dos Santos, D.V., G. Sousa e Silva, E.J. Weber, H. Hasenack, F.H. Sautter Groff, B. Todeschini, M.R. Borba, A.A. Rosa Medeiros, V.B. Leotti, C.W. Canal, and L.G. Corbellini (2017). Identification of Foot-and-mouth disease risk areas using a multi-criteria analysis approach. Plos One, 12(5).
21. Durrani, A.Z., F.A. Khan, A. Khan, I. Haq, and A. Khan. Comparative study of Immune potency of two different trivalent FMD Vaccines in Cattle, in Proceedings of 2017 14th International Bhurban Conference on Applied Sciences and Technology, M. Zafaruzzaman, et al., Editors. 2017. p. 170-173.
22. El-Khabaz, K.A.S. and A.A.T. Al-Hosary (2017). Detection and identification of Foot-and-mouth disease virus serotypes in Assiut governorate, Egypt. Journal of Advanced Veterinary and Animal Research, 4(1): 32-38.
23. El-Rahim, I.H.A.A., A.H. Asghar, A.M. Mohamed, and S.M. Fat'hi (2016). The impact of importation of live ruminants on the epizootiology of Foot-and-mouth disease in Saudi Arabia. Revue Scientifique Et Technique-Office International Des Epizooties, 35(3): 769-778.
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
35
24. Enright, J.A. and A. O'Hare (2017). Reconstructing disease transmission dynamics from animal movements and test data. Stochastic Environmental Research and Risk Assessment, 31(2): 369-377.
25. Ferreira, H.C.d.C., S.J. Pauszek, A. Ludi, C.L. Huston, J.M. Pacheco, V.T. Le, P.T. Nguyen, H.H. Bui, T.D. Nguyen, T. Nguyen, T.T. Nguyen, L.T. Ngo, D.H. Do, L. Rodriguez, and J. Arzt (2017). An Integrative Analysis of Foot-and-Mouth Disease Virus Carriers in Vietnam Achieved Through Targeted Surveillance and Molecular Epidemiology. Transboundary and Emerging Diseases, 64(2): 547-563.
26. Fishbourne, E., A.B. Ludi, G. Wilsden, P. Hamblin, B. Statham, A. Bin-Tarif, E. Brocchi, S. Grazioli, A. Dekker, P. Eble, and D.P. King (2017). Efficacy of a high potency O1 Manisa foot-and-mouth disease vaccine in cattle against heterologous challenge with a field virus from the O/ME-SA/Ind-2001 lineage collected in North Africa. Vaccine.
27. Galdo Novo, S., V. Malirat, E.D. Maradei, A.M. Espinoza, E. Smitsaart, A.R. Pedemonte, N. Mattion, and I.E. Bergmann (2017). Antigenic and immunogenic spectrum of Foot-and-mouth disease vaccine strain O1 Campos against representative viruses of topotypes that circulated in Asia over the past decade. Vaccine.
28. Govindaraj, G., B. Ganeshkumar, K.R. Nethrayini, R. Shalini, V. Balamurugan, B. Pattnaik, and H. Rahman (2017). Farm Community Impacts of Foot-and-Mouth Disease Outbreaks in Cattle and Buffaloes in Karnataka State, India. Transboundary and Emerging Diseases, 64(3): 849-860.
29. Guan, S.H. and G.J. Belsham (2017). Separation of Foot-and-mouth disease virus leader protein activities; identification of mutants that retain efficient self-processing activity but poorly induce eIF4G cleavage. Journal of General Virology, 98(4): 671-680.
30. Gubbins, S., J. Forster, S. Clive, D. Schley, S. Zuber, J. Schaaf, and D. Corley (2016). Thermal inactivation of Foot-and-mouth disease virus in extruded pet food. Revue Scientifique Et Technique-Office International Des Epizooties, 35(3): 965-972.
31. Hatem, A.A. and M.A. Talal (2016). The effect of FMD disease on 3rd trimester pregnant cows and their fetuses. Basrah Journal of Veterinary Research, 15(3): 475-480.
32. Hegde, R., S. Kowalli, K. Nagaraja, N.K. Dharanesha, C.M. Seema, T.A. Khan, G.V. Nagaraj, K. Srikala, K.J. Sudharshana, D. Nagaraju, S. Rao, P. Giridhara, and S.M. Byregowda (2016). Serosurveillance of Foot-and-mouth disease in Karnataka state, India: a 3 years study. Virusdisease, 27(3): 294-302.
33. Hole, K., F. Ahmadpour, J. Krishnan, C. Stansfield, J. Copps, and C. Nfon (2017). Efficacy of accelerated hydrogen peroxide(®) disinfectant on Foot-and-mouth disease virus, Swine vesicular disease virus and Senecavirus A. Journal of Applied Microbiology, 122(3): 634-639.
34. Houndje, E.M.B., C.A. Ogni, N. Noudeke, S. Farougou, A.K.I. Youssao, and T.M. Kpodekon (2016). Ethno-veterinary recipes of medicinal plants using for the treatment of Foot-and-mouth disease in Benin. International Journal of Biological and Chemical Sciences, 10(5): 2090-2107.
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
36
35. Howson, E.L.A., B. Armson, M. Madi, C.J. Kasanga, S. Kandusi, R. Sallu, E. Chepkwony, A. Siddle, P. Martin, J. Wood, V. Mioulet, D.P. King, T. Lembo, S. Cleaveland, and V.L. Fowler (2017). Evaluation of Two Lyophilized Molecular Assays to Rapidly Detect Foot-and-mouth disease virus Directly from Clinical Samples in Field Settings. Transboundary and Emerging Diseases, 64(3): 861-871.
36. Imran, I., I. Altaf, M. Ashraf, A. Javeed, N. Munir, and R. Bashir (2016). In vitro evaluation of antiviral activity of leaf extracts of Azadirachta indica, Moringa oleifera, and Morus alba against the Foot-and-mouth disease virus on BHK-21 cell line. Scienceasia, 42(6): 392-396.
37. Isabel de Avila, A., E. Moreno, C. Perales, and E. Domingo (2017). Favipiravir can evoke lethal mutagenesis and extinction of Foot-and-mouth disease virus. Virus Research, 233: 105-112.
38. Jonguk, L., YongwhaChung, 노병준, and 박대희 (2017). Crisis Management
Analysis of Foot-and-Mouth Disease Using Multi-dimensional Data Cube. The Journal of the Korea Contents Association, 17(5): 565-573.
39. Kaszta, Z., J. Marino, and E. Wolff (2017). Fine-scale spatial and seasonal rangeland use by cattle in a foot-and-mouth disease control zones. Agriculture Ecosystems & Environment, 239: 161-172.
40. Kim, S., H. Kwon, S. Park, H. Jeon, J.-k. Park, and J. Park (2017). Pilot-Scale Bio-Augmented Aerobic Composting of Excavated Foot-And-Mouth Disease Carcasses. Sustainability, 9(3).
41. Kim, T., S. Ryoo, J. Nah, M. Sagong, S. Lee, K. Lee, Y. Ko, J. Park, M. Lee, S. Wee, D. Tark, and B. Ku (2017). Complete genome sequence of a Foot-and-mouth disease virus of serotype O, isolated from Gochang, Republic of Korea, in 2016. Genome Announcements, 5(10): e01671-16.
42. Knowles, N.J., J. Wadsworth, K. Bachanek-Bankowska, and D.P. King (2016). VP1 sequencing protocol for Foot and mouth disease virus molecular epidemiology. Revue scientifique et technique (International Office of Epizootics), 35(3): 741-755.
43. Ko, C.-R., S.-S. Seol, and G. Kim (2017). Political Response to Foot-and-Mouth Disease: A Review of Korean News. Sustainability, 9(3).
44. Lawrence, P. and E. Rieder (2017). Insights into Jumonji C-domain containing protein 6 (JMJD6): a multifactorial role in Foot-and-mouth disease virus replication in cells. Virus Genes.
45. Lee, S.-Y., Y.-J. Lee, R.-H. Kim, J.-N. Park, M.-E. Park, M.-K. Ko, J.-H. Choi, J.-Q. Chu, K.-N. Lee, S.-M. Kim, D. Tark, H.-S. Lee, Y.-J. Ko, M.-G. Seo, J.-W. Park, B. Kim, M.-H. Lee, J.-S. Lee, and J.-H. Park (2017). Rapid Engineering for Vaccine and Challenge Viruses against Foot-and-Mouth Disease. Journal of Virology.
46. Leng, Y., M. Ren, Z. Meng, P. Zhang, Z. Yang, X. Yao, and Y. Wang (2017). Development of multiplex PCR for detection of 5 pathogenic viruses to pigs. Zhongguo Yufang Shouyi Xuebao, 39(2): 123-126.
47. Liu, X., Y. Fang, P. Zhou, Y. Lu, Q. Zhang, S. Xiao, Z. Dong, L. Pan, J. Lv, Z. Zhang, Y. Zhang, and Y. Wang (2017). Chimeric virus-like particles elicit protective immunity against serotype O Foot-and-mouth disease virus in guinea pigs. Applied Microbiology and Biotechnology.
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
37
48. Liu, Z., J. Shao, F. Zhao, G. Zhou, S. Gao, W. Liu, J. Lv, X. Li, Y. Li, H. Chang, and Y. Zhang (2017). Chemiluminescence immunoassay for the detection of antibodies against the 2C and 3ABC nonstructural proteins induced by infecting pigs with the Foot-and-mouth disease virus. Clinical and vaccine immunology : CVI.
49. Lotufo, C.M., I.E. Bergmann, N.M. Mattion, M. Wilda, and P.R. Grigera (2017). Recombinant Foot-and-mouth disease virus (FMDV) non-structural protein 3A fused to enhanced green fluorescent protein (EGFP) as a candidate probe to identify FMDV-infected cattle in serosurveys. Archives of Virology.
50. Lozovoi, D. (2016). Implementation of a complex of joint measures by member states of the Commonwealth of Independent States for prophylaxis and control of foot and mouth disease. Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, (4): 53-58.
51. Mahmoud, M.A. and S.A. Galbat (2017). Outbreak of foot and mouth disease and Peste des petits ruminants in sheep flock imported for immediate slaughter in Riyadh. Veterinary World, 10(2): 238-243.
52. Meyer, A., L. Zamir, A. Ben Yair Gilboa, B. Gelman, D.U. Pfeiffer, and T. Vergne (2017). Quantitative Assessment of the Risk of Release of Foot-and-Mouth Disease Virus via Export of Bull Semen from Israel. Risk analysis : an official publication of the Society for Risk Analysis.
53. Mischenko, A.V., V.A. Mischenko, P. Bolortuya, T. Purevkhuu, and K. Batamgalan (2017). Distribution of Foot-and-mouth disease in Mongolia. Veterinariya, (2): 23-25.
54. Mohanty, N.N., B. Das, L.N. Sarangi, S. Subramaniam, J.K. Mohapatra, and H.K. Panda (2016). Isolation and characterization of foot-and-mouth disease virus from Odisha, India. Tropical Biomedicine, 33(4): 753-760.
55. Nelson, N., D.J. Paton, S. Gubbins, C. Colenutt, E. Brown, S. Hodgson, and J.L. Gonzales (2017). Preclinical diagnosis: predicting its ability to improve control of farm-to-farm Foot-and-mouth disease transmission in cattle. Journal of Clinical Microbiology.
56. Pamaranon, N., S. Kasemsuwan, and T. Rukkwamsuk (2016). Quantitative risk assessment of the introduction of Foot-and-mouth disease virus by human into fattening pig farms in the compartmentalization. Journal of Kasetsart Veterinarians, 26(2): 83-99.
57. Paprocka, G. and A. Kesy (2017). Epidemiological situation of foot-and-mouth disease in 2014-2015 and the beginning of 2016. Medycyna Weterynaryjna, 73(3): 131-135.
58. Pomeroy, L.W., S. Bansal, M. Tildesley, K.I. Moreno-Torres, M. Moritz, N. Xiao, T.E. Carpenter, and R.B. Garabed (2017). Data-Driven Models of Foot-and-Mouth Disease Dynamics: AReview. Transboundary and Emerging Diseases, 64(3): 716-728.
59. Prajapati, B.M., J.P. Gupta, D.P. Pandey, G.A. Parmar, and J.D. Chaudhari (2017). Molecular markers for resistance against infectious diseases of economic importance. Veterinary World, 10(1): 112-120.
60. Puckette, M., T. Burrage, J.G. Neilan, and M. Rasmussen (2017). Evaluation of Gaussia luciferase and Foot-and-mouth disease virus 2A translational
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
38
interrupter chimeras as polycistronic reporters for transgene expression. Bmc Biotechnology, 17.
61. Rai, D.K., F. Diaz-San Segundo, G. Campagnola, A. Keith, E.A. Schafer, A. Kloc, T. de Los Santos, O. Peersen, and E. Rieder (2017). Attenuation of Foot-and-Mouth Disease Virus by Engineering Viral Polymerase Fidelity. Journal of virology.
62. Rodriguez Pulido, M. and M. Saiz (2017). Molecular Mechanisms of Foot-and-Mouth Disease Virus Targeting the Host Antiviral Response. Frontiers in Cellular and Infection Microbiology, 7.
63. Rout, M., S. Subramaniam, B. Das, J.K. Mohapatra, B.B. Dash, A. Sanyal, and B. Pattnaik (2017). Foot-and-mouth disease in wildlife population of India. Indian Journal of Animal Research, 51(2): 344-346.
64. Ryoo, S., T. Kim, J. Nah, M. Sagong, S. Lee, K. Lee, Y. Ko, J. Park, M. Lee, S. Wee, D. Tark, and B. Ku (2017). Complete genome sequence of a Foot-and-mouth disease virus of serotype O isolated from Gimje, Republic of Korea, in 2016. Genome Announcements, 5(10): e01694-16.
65. Santos, D.V.D., G.S.E. Silva, E.J. Weber, H. Hasenack, F.H.S. Groff, B. Todeschini, M.R. Borba, A.A.R. Medeiros, V.B. Leotti, C.W. Canal, and L.G. Corbellini (2017). Identification of Foot-and-mouth disease risk areas using a multi-criteria analysis approach. PloS one, 12(5): e0178464-e0178464.
66. Scott, K.A., N.M. Rathogwa, A.V. Capozzo, and F.F. Maree (2017). Evaluation of immune responses of stabilised SAT2 antigens of foot-and-mouth disease in cattle. Vaccine.
67. Senthilkumaran, C., M. Yang, H. Bittner, A. Ambagala, O. Lung, J. Zimmerman, L.G. Gimenez-Lirola, and C. Nfon (2017). Detection of genome, antigen, and antibodies in oral fluids from pigs infected with Foot-and-mouth disease virus. Canadian Journal of Veterinary Research, 81(2): 82-90.
68. Shi, X., G. Ma, Y. Bai, J. Hao, C. Qiao, Q. Liu, Y. Li, and B. Li (2017). Simultaneous detection of five bovine viruses by multiplex ligation-dependent probe amplification. Chinese Journal of Veterinary Science, 37(2): 224-230.
69. Singh, R., R. Alex, U. Singh, S. Kumar, G.S. Sengar, T.V. Raja, R.R. Alyethodi, A. Kumar, and R. Deb (2017). A Synonymous Mutation at Bovine α Vitronectin Domain of Integrin Host Receptor (ITGAV) Gene Effect the Susceptibility of Foot-and-Mouth Disease in Crossbred Cattle. Advances in Experimental Medicine and Biology.
70. Song, S., B. Zhao, P. Qu, D. Hu, Y. Sun, H. Dong, L. Yang, X. Song, and S. Pan (2017). Establishment of multiplex TaqMan real-time PCR for the detection of bovine viral diarrhea virus, Infectious bovine rhinotracheitis virus and Foot-mouth disease virus. Zhongguo Yufang Shouyi Xuebao, 39(2): 133-136.
71. Souley Kouato, B., F.M. Elliot, D.P. King, J. Hyera, N.J. Knowles, A.B. Ludi, V. Mioulet, G. Matlho, K. De Clercq, E. Thys, H. Marichatou, S. Issa, and C. Saegerman (2017). Outbreak investigations and molecular characterization of Foot-and-mouth disease viruses circulating in south-west Niger. Transboundary and Emerging Diseases.
72. Stenfeldt, C., J. Arzt, G. Smoliga, M. LaRocco, J. Gutkoska, and P. Lawrence (2017). Proof-of-concept study: profile of circulating microRNAs in Bovine
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
39
serum harvested during acute and persistent FMDV infection. Virology Journal, 14.
73. Tekleghiorghis, T., K. Weerdmeester, F. van Hemert-Kluitenberg, R.J.M. Moormann, and A. Dekker (2017). Foot-and-Mouth Disease Seroprevalence in Cattle in Eritrea. Transboundary and Emerging Diseases, 64(3): 754-763.
74. Van der Wiele, A. (2017). Foot-and-mouth disease training in Nepal. Tijdschrift Voor Diergeneeskunde, 142(2): 46-47.
75. Vandenbussche, F., D.J. Lefebvre, U. De Leeuw, S. Van Borm, and K. De Clercq (2017). Laboratory validation of two real-time RT-PCR methods with 5 '-tailed primers for an enhanced detection of Foot-and-mouth disease virus. Journal of Virological Methods, 246: 90-94.
76. Vosloo, W., A.D. Bastos, E. Kirkbride, D.J. Esterhuysen, D.J. vanRensburg, R.G. Bengis, D.W. Keet, and G.R. Thomson (1996). Persistent infection of African buffalo (Syncerus caffer) with SAT-type Foot-and-mouth disease viruses: Rate of fixation of mutations, antigenic change and interspecies transmission. Journal of General Virology, 77: 1457-1467.
77. Vu, L.T., N.T. Long, B. Brito, C. Stenfeldt, N.T. Phuong, B.H. Hoang, S.J. Pauszek, E.J. Hartwig, G.R. Smoliga, P.P. Vu, L.T.V. Quang, V.V. Hung, N.D. Tho, P.V. Dong, P.Q. Minh, M. Bertram, I.H. Fish, L.L. Rodriguez, D.H. Dung, and J. Arzt (2017). First detection of Foot-and-mouth disease virus O/Ind-2001d in Vietnam. Plos One, 12(6).
78. Wada, M., M. Stevenson, N. Cogger, and T. Carpenter (2017). Evaluation of the Control Strategy for the 2010 Foot-and-Mouth Disease Outbreak in Japan Using Disease Simulation. Transboundary and Emerging Diseases, 64(3): 978-989.
79. Willeberg, P.W., M. AlKhamis, A. Boklund, A.M. Perez, C. Enoe, and T. Halasa (2017). Semiquantitative Decision Tools for FMD Emergency Vaccination Informed by Field Observations and Simulated Outbreak Data. Frontiers in Veterinary Science, 4: 43-43.
80. Wnek, J. (2016). Eradication of Foot-and-mouth disease in Poland in 1918-1939. Zycie Weterynaryjne, 91(12): 944-945.
81. Wungak, Y.S., O.O. Ishola, B.O. Olugasa, D.D. Lazarus, D.O. Ehizibolo, and H.G. Ularamu (2017). Spatial pattern of foot-and-mouth disease virus serotypes in North Central Nigeria. Veterinary World, 10(4): 450-456.
82. Yan, D., Z. Teng, S. Sun, S. Jiang, H. Dong, Y. Gao, Y. Wei, W. Qin, X. Liu, H. Yin, and H. Guo (2017). Foot-and-mouth disease virus-like particles as integrin-based drug delivery system achieve targeting anti-tumor efficacy. Nanomedicine: Nanotechnology, Biology, and Medicine, 13(3): 1061-1070.
83. Yan, H., J. Wang, M. Zhu, H. Miao, Z. Peng, H. Li, and A. Xin (2017). Complete Genome Sequence of Foot-and-Mouth Disease Virus Serotype O Strain YNTBa from Yunnan Province of China. Genome Announcements, 5(22).
84. Yang, Y., Q. Zhao, Z. Li, L. Sun, G. Ma, S. Zhang, and Z. Su (2017). Stabilization study of inactivated Foot and mouth disease virus vaccine by size-exclusion HPLC and differential scanning calorimetry. Vaccine.
85. You, S.-H., T. Kim, J.-H. Choi, G. Park, K.-N. Lee, B. Kim, M.-H. Lee, H.-S. Kim, S.-M. Kim, and J.-H. Park (2017). Coinjection of a vaccine and anti-viral
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
40
agents can provide fast-acting protection from Foot-and-mouth disease. Antiviral Research, 143: 195-204.
86. Zeng, B., R. Li, H. Xiao, and S. Chen (2017). Advances in molecular genetic basis of disease resistance differences among domestic cattle breeds. Acta Veterinaria et Zootechnica Sinica, 48(2): 193-200.
87. Zhang, F., E. Perez-Martin, N. Juleff, B. Charleston, and J. Seago (2017). A replication-competent Foot-and-mouth disease virus expressing a luciferase reporter. Journal of Virological Methods, 247: 38-44.
88. Zhao, B., Y. Liu, Y. Chen, P. Ji, J. Wang, C. Liu, S. Yang, and G. Zhang (2017). Soluble expression and immunoreactivity analysis of FMDV VP0 and VP1 protein. Journal of Henan Agricultural Sciences, 46(2): 105-110.
89. Zhao, F.-R., Y.-L. Xie, Z.-Z. Liu, J.-J. Shao, S.-F. Li, P. Zhou, Y.-G. Zhang, and H.-Y. Chang (2017). Transcriptomic Analysis of porcine PBMCs in Response to FMDV Infection. Acta Tropica.
90. Zhao, H., G. Teni, J. Lu, T. Huang, Q. Xiao, and L. Geri (2017). Effect of various types FMDV VP1 gene epitope embedded protein SLP-MultiVP1 on IgG subtypes of different immune mice. Chinese Journal of Veterinary Science, 37(2): 262-265.
91. Zhu, Z., C. Li, X. Du, G. Wang, W. Cao, F. Yang, H. Feng, X. Zhang, Z. Shi, H. Liu, H. Tian, D. Li, K. Zhang, X. Liu, and H. Zheng (2017). Foot-and-mouth disease virus infection inhibits LGP2 protein expression to exaggerate inflammatory response and promote viral replication. Cell Death and Disease, 8(4): e2747-e2747.
The content of this report is the property of WRLFMD®, The Pirbright Institute.
Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, [email protected]
41
6. Annex 3
RECOMMENDATIONS FROM WRLFMD® ON FMD VIRUS STRAINS TO BE INCLUDED IN FMDV ANTIGEN BANKS (FOR FMD-FREE COUNTRIES)
June 2017:
Note: Virus strains are NOT listed in order of importance
High Priority
A/ASIA/G-VII(G-18)* O Manisa
O PanAsia-2 (or equivalent) Asia 1 Shamir
A Iran-05 (or A TUR 06) A22 Iraq
A24 Cruzeiro O BFS or Campos
SAT 2 Saudi Arabia (or equivalent i.e. SAT 2 Eritrea)
Medium Priority
A Eritrea-98 SAT 2 Zimbabwe
SAT 1 South Africa A Malaysia 97 (or Thai equivalent such as A/Sakolnakorn/97)
A Argentina 2001 O Taiwan 97 (pig-adapted strain or Philippine
equivalent)
Low Priority
A Iran ‘96 A Iran ‘99
A Iran 87 or A Saudi Arabia 23/86 (or equivalent) A15 Bangkok related strain A87 Argentina related strain
C Noville SAT 2 Kenya SAT 1 Kenya
SAT 3 Zimbabwe
Note: Discussions are currently underway to adopt a risk-based approach for different FMD viral lineages to identify priority vaccines for use in Europe and other FMD-free settings.
*Recent in vitro data from WRLFMD for serotype A viruses from Saudi Arabia and Iran highlights an apparent gap in vaccines supplied by international manufacturers for this viral lineage.
